Vitrectomy is a surgery to remove some or all of the vitreous humor from the eye. Vitreous tamponades are essentials used in vitrectomy procedures conducted in the human eye that either assist in healing or reattachment of the retina or provide a replacement to a clouded vitreous humor. Vitreous substitutes have been developed both as an intraoperative and as a postoperative tool for the surgical treatment of complicated vitreoretinal diseases. The retinal tamponade acts to hold the retina in place or temporarily seal off holes in the retina. The use of endotamponade agents has gained a major role in the management of macular complications of high myopia. The choice of different intraocular tamponade agents depends on the location of retinal break(s), compliance of postoperative posture, type of vitreoretinal disease(s), and duration required for the tamponade.
The global vitreous tamponades market report provides market size (Revenue US$ Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021).
The global vitreous tamponades market segmentation is based on product types (Gaseous tamponades, liquid tamponades, silicone oil, per fluorocarbon liquids).
The global vitreous tamponades market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global vitreous tamponades market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global vitreous tamponades market and included in this report are Alcon, Inc., Alchimia srl, Carl Zeiss Meditec AG, Croma – Pharma AG, Dutch Ophthalmic Research Center B.V., Fluoron GmbH, and Valeant Pharmaceuticals International, Inc. (Bausch + Lomb).